Compare IRWD & KRNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IRWD | KRNY |
|---|---|---|
| Founded | 1998 | 1884 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.3M | 569.6M |
| IPO Year | 2009 | 2014 |
| Metric | IRWD | KRNY |
|---|---|---|
| Price | $4.83 | $9.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $6.18 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 2.3M | 419.5K |
| Earning Date | 11-05-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 4.81% |
| EPS Growth | N/A | ★ 35.71 |
| EPS | ★ 0.91 | 0.16 |
| Revenue | ★ $298,276,000.00 | $2,580,000.00 |
| Revenue This Year | $59.19 | $10.19 |
| Revenue Next Year | $4.80 | $12.02 |
| P/E Ratio | ★ $5.33 | $57.16 |
| Revenue Growth | 8.88 | ★ 36.00 |
| 52 Week Low | $2.95 | $6.23 |
| 52 Week High | $5.78 | $10.24 |
| Indicator | IRWD | KRNY |
|---|---|---|
| Relative Strength Index (RSI) | 76.30 | 45.61 |
| Support Level | $3.90 | $8.89 |
| Resistance Level | N/A | $9.63 |
| Average True Range (ATR) | 0.24 | 0.23 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 93.10 | 32.81 |
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income from their clients.